Alembic Pharmaceuticals has received final approval from the USFDA for its generic version of Paliperidone extended-release tablets, used to treat schizophrenia and schizoaffective disorder. The approval covers strengths of 1.5 mg, 3 mg, 6 mg, and 9 mg. The market size for these tablets is estimated at USD 48 million for the year ending June 2024.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.